On Feb. 18, biotechnology company New Horizon Health (6606.HK) raised HK$2.42 billion in an initial public offering (IPO) in Hong Kong, with the firm’s IPO being oversubscribed 4133 times.
On Feb. 18, biotechnology company New Horizon Health (6606.HK) raised HK$2.42 billion in an initial public offering (IPO) in Hong Kong, with the firm’s IPO being oversubscribed 4133 times.
On Feb. 18, biotechnology company New Horizon Health (6606.HK) raised HK$2.42 billion in an initial public offering (IPO) in Hong Kong, with the firm’s IPO being oversubscribed 4133 times.
On Feb. 18, biotechnology company New Horizon Health (6606.HK) raised HK$2.42 billion in an initial public offering (IPO) in Hong Kong, with the firm’s IPO being oversubscribed 4133 times.
On Feb. 18, biotechnology company New Horizon Health (6606.HK) raised HK$2.42 billion in an initial public offering (IPO) in Hong Kong, with the firm’s IPO being oversubscribed 4133 times.
On Feb. 18, biotechnology company New Horizon Health (6606.HK) raised HK$2.42 billion in an initial public offering (IPO) in Hong Kong, with the firm’s IPO being oversubscribed 4133 times.
On Feb. 18, biotechnology company New Horizon Health (6606.HK) raised HK$2.42 billion in an initial public offering (IPO) in Hong Kong, with the firm’s IPO being oversubscribed 4133 times.
On Feb. 18, biotechnology company New Horizon Health (6606.HK) raised HK$2.42 billion in an initial public offering (IPO) in Hong Kong, with the firm’s IPO being oversubscribed 4133 times.
New Horizon Health on Nov. 25 announced that their flagship product, ColoClear, has been approved by the National Medical Products Administration for the screening of Colorectal Cancer (CRC) and precancerous lesion.
Life sciences company BioMap was formally announced on Sept. 25, led by Baidu CEO Robin Li as chairman and Baidu Ventures (BV) CEO Liu Wei as co-founder and CEO.
